Comparative Pharmacology
Head-to-head clinical analysis: AMERGE versus ZOMIG ZMT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMERGE versus ZOMIG ZMT.
AMERGE vs ZOMIG-ZMT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin 5-HT1B/1D receptor agonist; binds to 5-HT1B and 5-HT1D receptors on cranial blood vessels and trigeminal nerve endings, causing vasoconstriction and inhibition of pro-inflammatory neuropeptide release.
Selective serotonin 5-HT1B/1D receptor agonist; causes vasoconstriction of cranial blood vessels, inhibits trigeminal nerve transmission, and reduces neurogenic inflammation.
2.5 mg orally at onset of migraine; may repeat after 4 hours if needed, maximum 5 mg in 24 hours.
2.5 mg orally at onset of migraine; may repeat after 2 hours if needed. Maximum 10 mg in 24 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 26 hours (range 13-40 hours). This long half-life allows for once-daily dosing for prophylaxis, but may prolong the duration of adverse effects.
Terminal elimination half-life is approximately 3 to 3.5 hours for zolmitriptan and its active metabolite N-desmethyl zolmitriptan has a similar half-life. This supports a typical dosing interval of at least 2 hours between doses.
Renal excretion accounts for approximately 50% of the dose, with about 40% as unchanged drug and 10% as metabolites. Fecal excretion accounts for 30% of the dose. The remainder is unknown.
Approximately 60-70% of the administered dose is excreted in urine, primarily as metabolites (active N-desmethyl zolmitriptan and inactive indoleacetic acid derivatives), with about 10-15% as unchanged drug. Fecal excretion accounts for about 20-30% of the dose.
Category C
Category C
Triptan Antimigraine
Triptan Antimigraine